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Background: The purpose of the present study was to investigate the feasibility of using volumetric modulated arc
therapy with SmartArc (VMAT-S) to achieve radiation delivery efficiency higher than that of intensity-modulated
radiotherapy (IMRT) and helical tomotherapy (HT) when treating endometrial cancer, while maintaining plan quality.
Methods: Nine patients with endometrial cancer were retrospectively studied. Three plans per patient were
generated for VMAT-S, IMRT and HT. The dose distributions for the planning target volume (PTV), organs at risk
(OARs) and normal tissue were compared. The monitor units (MUs) and treatment delivery time were also
evaluated.
Results: The average homogeneity index was 1.06, 1.10 and 1.07 for the VMAT-S, IMRT and HT plans, respectively.
The V40 for the rectum, bladder and pelvis bone decreased by 9.0%, 3.0% and 3.0%, respectively, in the VMAT-S plan
relative to the IMRT plan. The target coverage and sparing of OARs were comparable between the VMAT-S and HT
plans. The average MU was 823, 1105 and 8403 for VMAT-S, IMRT and HT, respectively; the average delivery time
was 2.6, 8.6 and 9.5 minutes, respectively.
Conclusions: For endometrial cancer, the VMAT-S plan provided comparable quality with significantly shorter
delivery time and fewer MUs than with the IMRT and HT plans. In addition, more homogeneous PTV coverage and
superior sparing of OARs in the medium to high dose region were observed in the VMAT-S relative to the IMRT
plan.
Keywords: Endometrial cancer, Helical tomotherapy, Intensity-modulated radiation therapy, Volumetric modulated
arc therapyBackground
Endometrial cancer is one of the most common gyneco-
logic cancers in the world. Whole pelvic radiation therapy
(WPRT) can reduce the rate of pelvic disease recurrence
in patients who have undergone hysterectomy for endo-
metrial cancer [1,2]. For whole pelvic radiation therapy,
intensity-modulated radiation therapy (IMRT) and helical
tomotherapy (HT) have been shown to give a more con-
formal dose distribution than conventional radiotherapy,* Correspondence: ruijyang@yahoo.com
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reproduction in any medium, provided the orwith better sparing of adjacent critical structures [3-6].
However, the IMRT and HT techniques also have draw-
backs. The prolonged treatment delivery time required for
IMRT and HT relative to three-dimensional conformal
radiotherapy may worsen the accuracy of treatment be-
cause of increased intra-fractional patient motion. Add-
itionally, patient throughput is reduced using IMRT and
HT with economic consequences. Another issue of con-
cern is the higher number of monitor units (MU) used in
IMRT and HT, which can increase the number of second-
ary cancers after curative treatment [7]. Recently, volumet-
ric modulated arc therapy (VMAT) has been introduced
to address the above mentioned issues. The potentiald. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IMRT are obtained with enhanced degrees of freedom in
continuously modulating the multileaf collimator (MLC)
field shape, gantry rotation speed and dose rate. However,
the potential advantages of VMAT are highly dependent
on the actual optimization algorithm in the treatment
planning system (TPS). Only algorithms which handle the
increased degrees of freedom appropriately will have the
potential to achieve the potential advantages offered by
VMAT. It is therefore important to validate the clinical
applicability of VMAT algorithms. The performance of
RapidArc (the VMAT algorithm used in Eclipse TPS plans
for Varian accelerators) has been shown to provide super-
ior or equivalent dose distributions relative to standard
IMRT for the treatment of prostate, cervical, anal canal,
lung, brain and head and neck cancer within the prelimin-
ary planning studies [8-13].
Recently, the VMAT optimizer in the Pinnacle3
SmartArc treatment planning module (Philips Medical
Systems, Madison, WI, USA) was used in combination
with a Varian Trilogy linear accelerator in our department.
Studies regarding the clinical performance of these sys-
tems are therefore of interest. In addition, more radiation
fields are used in VMAT and HT than in IMRT. Conse-
quently, a greater volume of normal tissue will be exposed
to lower radiation doses. There are some concerns with
regard to the increase in the normal tissue (NT) integral
dose using VMAT as a potential risk factor for the devel-
opment of secondary cancers. For a better assessment of
the risks of the development of a second malignancy, it is
necessary to evaluate the integral dose (ID) deposited in
critical structures and normal tissue. To date, no study has
been published concerning the evaluation of the dosimetry
for WPRT using SamrtArc-based VMAT (VMAT-S) and
the Varian linear accelerator in the treatment of postoper-
ative endometrial cancer patients, especially in terms of
the ID to NT and organs at risk (OARs). The aim of the
present study was to compare the VMAT-S plan with the
IMRT and HT plans for whole pelvic radiation therapy
involving postoperative endometrial cancer patients,
with a focus on the volume of NT and OARs receiving
low radiation doses, and the IDs deposited in NT and
OARs.
Methods
Patient selection and simulation
Nine consecutive patients who had been treated with
postoperative WPRT for endometrial cancer were retro-
spectively selected for this study. The study was approved
by Ethics Committee of Peking University Third Hospital
and informed consent was obtained. All patients had
undergone total abdominal hysterectomy and bilateral
salpingo-oophorectomy, pelvic and/or para-aortic lymph
node dissection/sampling, with no gross residual disease.Of the 9 patients, 7 were simulated and treated in the
supine position and 2 in the prone position on a belly
board. A vaginal marker was carefully inserted to indicate
the position of the vaginal apex, without distortion of the
vagina. All patients were instructed to drink 1500 ml
of water at 1 hour before simulation and treatment;
they were immobilized using a thermoplastic mask and
scanned from the T12 vertebrate to mid-thigh using oral
and i.v. contrast. The image sets were transferred to the
Pinnacle planning system for contouring and planning.
Definition and contour of targets
The clinical target volume (CTV) was delineated accord-
ing to the consensus guidelines of the RTOG, GOG,
NCIC, ESTRO and ACR groups [14]. The CTV included
pelvic lymph node regions (common, internal and exter-
nal iliacs), the proximal 3.0 cm of the vagina and parava-
ginal tissues for all of the patients. For patients with
cervical stromal invasion, the presacral lymph node re-
gion was also contoured to the inferior border of the S2
vertebra. A margin of 0.7 cm was added to the “vessels”
contour in all dimensions and modified using anatomic
boundaries (as clinically indicated for individual pa-
tients) to create the nodal clinical target volume, from
which the pelvic bones, femoral heads and vertebral
bodies were excluded. The CTV was expanded by 1 cm
to create the planning target volume (PTV).
Definition and contour of OARs and NT
Contours for OARs included the bladder, rectum, small
intestine, colon and pelvic bones. The superior and
inferior extents of OARs were outlined on all CT slices
in which portions of the PTV existed, as well as at an
additional 2 cm superior and inferior to the limits of the
PTV. The rectum was defined from the rectosigmoid
flexure to the anus. The small intestine and colon were
contoured together as one structure referred to as the
“bowel”. The bowel volume was contoured as individual
loops. The pelvic bones were defined and contoured
according to a previously published study [15]. The ex-
ternal contours of all the bones within the pelvis were
delineated for each patient. The entire bony contour
was divided into three subsites: the ilium, lower pelvis
and lumbosacral spine. No expansion of any of these
OARs was made to account for organ motion and set
up error. The whole body was contoured as the entire
volume of all slices where the PTV existed, as well as at
an additional 2 cm superior and inferior to the PTV.
The NT was defined as the whole body within the skin
surface minus the PTV.
Treatment planning
The VMAT-S, IMRT and HT plans were all generated
using 6-MV photon beams for each patient. The VMAT-
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planning system, version 9.2 (Philips Radiation Oncology
Systems, Fitchburg, WI, USA), for delivery using a Varian
Trilogy linear accelerator equipped with a Millennium
MLC. The HT plan was generated using a tomotherapy
planning system (Hi-Art Tomotherapy 2.2.4.1, TomoTher-
apy, Madison, WI, USA). All plans were generated for
VMAT-S, IMRT and HT using the same plan objectives
(Table 1).
IMRT plan optimization was performed using the
Direct Machine Parameter Optimization algorithm in the
Pinnacle3 treatment planning system. Based on the find-
ings of previous studies [5,16], nine coplanar beams were
used. Fields were set with an equal spacing of 40° and a
starting angle of 0°. The minimum segment area was set
to 5 cm2 and the minimum number of segment MUs was
five. A collapsed-cone convolution algorithm was used to
calculate the dose distribution, with a dose grid resolution
of 4 mm.
The VMAT-S plans were optimized using the Pinnacle3
SmartArc module. The details regarding the SmartArc
planning algorithm have been described by Bzdusek et al.
[17]. All VMAT-S plans were generated using one dual
arc, the first clockwise from 181–179°, and the second
counterclockwise from 179–181°, with a final control
point resolution of 2°. To allow maximal modulation per
arc, no limitation on the delivery time was used during the
optimization. Continuous gantry motion, dose-rate vari-
ation and MLC motion were approximated by optimizing
individual beams at 2° gantry angle increments. The
choice of this resolution was based on preliminary plan-
ning exercises to get better plan quality utilizing the higher
degree of modulation. Other planning parameters were
MLC motion speed 0–2.5 cm/s, gantry rotation speed
0.5–4.8 degrees/s and dose rate 0–600 MU/min.
For HT plans, CT datasets with structures that had
been contoured in the Pinnacle system were transferred
to the Tomotherapy planning system using the Digital
Imaging and Communication in Medicine RT protocol.
The optimization was guided using dose volume objec-
tives and constraints, precedence, importance and pen-
alty parameters, which were set based on the results of
IMRT and our pilot study. The field width was 2.5 cm,
the pitch (ratio of the distance traveled by the treatmentTable 1 The dose-volume objectives and constraints used
in VMAT-S, IMRT and HT plans
Structures Objectives and constraints
PTV Minimal dose, 47.5 Gy; maximal dose, 55 Gy; ≥95%
of PTV receiving 50 Gy
Bowel ≤35% of bowel receiving ≥35 Gy
Bladder ≤40% of bladder receiving ≥40 Gy
Rectum ≤60% of rectum receiving ≥40 Gycouch per rotation to the fan beam thickness) was 0.3
and the modulation factor was 3.0.
Dosimetric comparison
For the convenience of comparison, all plans were nor-
malized to deliver 50 Gy to 95% of the PTV in 25 frac-
tions. The DVHs of the VMAT-S, IMRT and HT plans
were compared in terms of coverage of the PTV, OARs
and normal tissue sparing, and the ID deposited in the
OARs and NT. The parameters analyzed included the per-
centage of the PTV that received 95%, 100%, 105% and
110% of the prescription dose (PTV95, PTV100, PTV105
and PTV110, respectively), the homogeneity index (HI)
and the conformity index (CI). The HI was defined as the
minimum dose in 5% of the PTV/minimum dose in 95%
of the PTV (D5%/D95%). The lower (closer to 1) the HI
is, the better the dose homogeneity. Since not all regions
of the PTV were covered by the prescribed dose, the CI
was calculated as follows: CI = CF (cover factor) × SF (spill
factor), where the CF was defined as the percentage of the
PTV volume receiving at least the prescribed dose and
the SF as the volume of the PTV receiving at least the
prescription dose relative to the total prescription dose
volume. The closer the CI value is to 1, the better the
dose conformity. To quantify the dose distribution of
OARs and NT at different dose levels, the percentage
volume of the OARs and NT receiving a dose of 10, 20,
30, 40 and 50 Gy (V10, V20, V30, V40 and V50, respectively)
were evaluated and compared in the VMAT-S, IMRT and
HT plans. The mean dose and ID deposited in the OARs
and NT were also compared. The ID is equal to the mean
dose multiplied by the volume of each structure.
Statistics
Dosimetric differences regarding VMAT-S were com-
pared with those regarding IMRT and HT. Statistical sig-
nificance was evaluated using the paired two-tailed
Student t test. A 2-tailed P-value < 0.05 was considered
as being statistically significant. Analyses were per-
formed using the Statistical Package for Social Science,
version 13.0, software (SPSS, Chicago, IL, USA).
Results
PTV coverage
For all 9 cases, clinically acceptable plans could be gener-
ated for VMAT-S, IMRT and HT. The typical dose distri-
bution and the dose volume histogram comparison were
given in Figures 1 and 2. The data for PTV coverage are
summarized in Table 2. The VMAT-S plan significantly
improved the PTV dose homogeneity as compared with
the IMRT plan. No significant difference was found in
PTV dose homogeneity between the VMAT-S and HT
plans. The average HI was 1.06, 1.10 and 1.07 for the
VMAT-S, IMRT and HT plans, respectively. The mean
Figure 1 Representative axial computed tomography slices
showing isodose distributions. (A) IMRT. (B) VMAT-S.
(C) Tomotherapy. PTV is shown in red, CTV in slate blue. Isodose
lines are indicated as follows: inverse grey, 5250 cGy; yellow,
5000 cGy; orange, 4750 cGy; purple, 4000 cGy; green, 3000 cGy; sky
blue, 2000 cGy; and blue 1000 cGy.
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IMRT and HT plans, respectively; the difference in con-
formity between the VMAT and IMRT or HT plans was
not statistically significant. Specifically, for the VMAT-S,
IMRT and HT plans the mean PTV105 was 40.5%, 67.1%
and 16.7%, respectively, and the mean PTV110 was 0.00%,
5.30% and 0.20%, respectively. The average PTV100 was
95.1%, 95.6% and 95.8% for the VMAT-S, IMRT and HT
plans, respectively. No difference in PTV Dmean and ID
between the VMAT-S and IMRT, or HT plans was found.
OARs and NT sparing
The dose-volume histogram data for the OARs and NT
are listed in Table 3. As compared with the IMRT plan,the VMAT-S plan significantly reduced the irradiated
volume of the OARs and NT receiving medium to high
doses. For the rectum, the V30 and V40 decreased by
11.0% and 9.0%, respectively. The V30 and V40 of pelvis
bone decreased by 5.0% and 3.0%, respectively. The V30
and V40 of the bladder also decreased by 3.0% and 3.0%,
respectively. However the VMAT-S plan slightly in-
creased the volume of the bowel, bladder and pelvis
bone receiving doses <20 Gy relative to the IMRT plan.
The V20 increased by 4.0%, 5.0% and 8.0% for the bowel,
bladder and pelvis bone, respectively. In addition, the V5,
V10 and V20 of the NT also increased by 6.0%, 11.0% and
3.0%, respectively. When comparing the VMAT-S plans
with the HT plans, the sparing of the OARs and NT was
found to be very similar. Even the volumes receiving
more than 20 Gy in the OARs were reduced using the
HT plan, while the low dose volumes of the OARs were
increased, but the difference was not statistically
significant.
Integral dose to the OARs and NT
The integral doses deposited in the OARs and NT using
the VMAT-S, IMRT and HT plans are given in Table 4.
No significant difference was found using the VMAT-S
plans relative to the IMRT or HT plans.
MU and treatment delivery time
The MU was on average 1105 for IMRT, 823 for
VMAT-S and 8403 for HT. As compared with IMRT,
the MU was reduced by 25.5% using VMAT. The
treatment delivery time was on average 8.6 minutes
for IMRT, 2.6 minutes for VMAT-S and 9.5 minutes
for HT. Relative to IMRT and HT, the average treatment
time was reduced by 6.0 minutes (69.8%) and 6.9 minutes
(72.6%), respectively using the VMAT plan. The treatment
delivery time was defined as the time from first beam turn
on until last beam turn off.
Discussion
We evaluated the VMAT plans based on SmartArc using
a Varian Trilogy linear accelerator; this accelerator is now
used clinically for the treatment of endometrial cancer in
our department, a complex situation often encountered in
the clinic. As compared with the IMRT plan, the VMAT-S
plan provided a more homogeneous dose distribution in
the PTV and better sparing of the OARs and NT in the
medium to high dose region; a slightly larger volume of
normal tissue received a radiation dose of 20 Gy. No sig-
nificant difference was found between the VMAT-S and
HT plans. The major benefits of VMAT-S plan were mani-
fested in the faster delivery time and lower MU relative to
the IMRT and HT plans. Luca et al. [18] compared fixed
field IMRT with VMAT for cervical cancer as planned/
delivered using an Eclipse/Varian linear accelerator. They
Figure 2 Representative dose–volume histograms for (a) IMRT Vs VMAT-S, (b) tomotherapy. The curves of IMRT and Tomotherapy
indicated in solid line, those of SmartArc indicated in dashed lines. The colors of the curves indicated as follows: red, PTV; forest, rectum; skyblue,
bladder; purple, bowel; blue, pelvic bones; skin, normal tissue.
Table 2 Summary of PTV coverage data for VMAT-S, IMRT and HT plans xσÞð
PTV95 (%) PTV100 (%) PTV105 (%) PTV110 (%) Dmean (Gy) CI HI
Mean (VMAT-S) 99.82 95.10 40.50 0.00 52.01 0.89 1.06
Mean (IMRT) 99.91 95.60 67.10 5.30 52.51 0.87 1.10
P 0.53 0.68 0.03 0.01 0.51 0.07 0.01
Mean (HT) 99.61 95.80 16.70 0.20 51.45 0.87 1.07
P 0.37 0.83 0.00 0.71 0.08 0.06 0.25
PTV: planning target volume, VMAT-S: volumetric modulated arc therapy with SmartArc, IMRT: intensity-modulated radiotherapy, HT: helical tomotherapy,
Dmean: mean dose, CI: conformity index, HI: homogeneity index.
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Table 3 Summary of OARs and NT dose distribution for VMAT-S, IMRT and HT plans x σð Þ
Structures V10 V20 V30 V40 V50 Dmean (Gy)
Bowel Mean (VMAT-S) 0.88 0.70 0.39 0.22 0.08 27.35
Mean (IMRT) 0.83 0.66 0.40 0.22 0.09 26.72
P 0.02 0.03 0.15 0.27 0.39 0.02
Mean (HT) 0.91 0.72 0.38 0.19 0.08 26.91
P 0.07 0.08 0.13 0.10 0.61 0.03
Rectum Mean (VMAT-S) 0.99 0.96 0.82 0.54 0.25 40.33
Mean (IMRT) 0.98 0.96 0.93 0.63 0.27 42.40
P 0.19 0.52 0.03 0.00 0.06 0.01
Mean (HT) 1.00 0.98 0.85 0.57 0.25 40.99
P 0.21 0.31 0.31 0.08 0.36 0.12
Bladder Mean (VMAT-S) 1.00 0.96 0.67 0.35 0.16 36.23
Mean (IMRT) 0.99 0.91 0.70 0.38 0.17 36.33
P 0.36 0.03 0.03 0.04 0.37 0.17
Mean (HT) 1.00 0.86 0.65 0.33 0.14 35.09
P 0.52 0.02 0.16 0.08 0.38 0.06
Pelvic bones Mean (VMAT-S) 0.91 0.73 0.40 0.22 0.08 27.85
Mean (IMRT) 0.84 0.65 0.45 0.25 0.09 27.28
P 0.00 0.00 0.03 0.03 0.17 0.13
Mean (HT) 0.91 0.69 0.41 0.24 0.09 28.22
P 0.51 0.08 0.07 0.06 0.53 0.61
Normal tissue Mean (VMAT-S) 0.79 0.45 0.21 0.11 0.05 20.48
Mean (IMRT) 0.68 0.42 0.21 0.12 0.05 19.77
P 0.00 0.03 0.15 0.15 0.25 0.08
Mean (HT) 0.81 0.42 0.17 0.06 0.03 20.56
P 0.35 0.10 0.07 0.09 0.12 0.15
OARs: organs at risk, NT: normal tissue, VMAT-S: volumetric modulated arc therapy with SmartArc, IMRT: intensity-modulated radiotherapy, HT: helical tomotherapy,
V10, V20, V30, V40 and V50: the percentage volume of the OARs and NT receiving a dose of 10, 20, 30, 40 and 50 Gy, respectively, D mean: mean dose.
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sparing of the rectum, bladder and small bowel in the
medium to high dose region.
The volumes receiving doses of >30 Gy in the bladder,
rectum and pelvis bone were reduced using the VMATTable 4 ID delivered to the OARs and NT for the VMAT-S,
IMRT and HT plans xσÞð
Plans VMAT-S IMRT HT
Mean Mean P Mean P
(Gy × L) (Gy × L) (Gy × L)
Bowel 23.83 23.22 0.35 23.45 0.21
Rectum 3.18 3.34 0.36 3.26 0.32
Bladder 11.40 11.98 0.17 11.02 0.20
Pelvic bones 36.60 36.10 0.21 37.50 0.35
Normal tissue 262.30 258.50 0.11 265.12 0.09
ID: integral dose, OARs: organs at risk, NT: normal tissue, VMAT-S: volumetric
modulated arc therapy with SmartArc, IMRT: intensity-modulated radiotherapy,
HT: helical tomotherapy.plan relative to the IMRT plan, whereas the volumes re-
ceiving doses <20 Gy were increased for the bladder and
pelvis bone. This was because in IMRT the dose is deliv-
ered using relatively few beam angles as compared with
VMAT. The improved sparing of the bladder, rectum
and pelvis bone at medium to high doses using VMAT
as compared with IMRT is expected to further reduce
the acute and late toxicities, especially for patients re-
quiring a local boost and concurrent/sequential chemo-
therapy. This is also relevant to patients not suitable for
the high dose rate boost. As an arc-based approach to
the delivery of IMRT, VMAT can deliver a more homo-
geneous dose to the target volume with a greater degree
of freedom of intensity modulation. As expected, greater
volumes of bowel, pelvic bones and NT received radi-
ation doses ranging from 5–20 Gy, as compared with
IMRT. The increased low dose bath effect in the NT and
pelvic bones might be explained by the larger and longer
target volumes exposed to more radiation beams in the
arc pattern of radiation delivery involved in VMAT. Lian
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cancer patients the use of HT increased low dose irradi-
ation of the normal tissue and skeleton in pelvic and
para-aortic radiotherapy. A greater volume of pelvic
bones exposed to a dose of 2–20 Gy could increase the
risk of hematologic suppression [14,15] and bone frac-
ture [19]. A larger volume of NT received a low dose of
2–20 Gy using VMAT-S relative to IMRT. Some con-
cerns have been raised regarding the risk of secondary
cancers in NT irradiated to low dose. Given the better
sparing of OARs, and the longer life expectancy of older
patients with endometrial cancer treated using VMAT-S,
its benefits outweigh its pitfalls. Investigation of this
issue was beyond the scope of this study, and has previ-
ously been addressed and discussed [7]. It is possible
that the low dose volume in the pelvic bones and NT
could be decreased in the planning process by introducing
the corresponding dose volume constraints in VMAT-S
and HT. Because the present study was designed to be a
comparative dosimetric evaluation of VMAT-S, IMRT and
HT plans, we did not use any constraints regarding the
pelvic bones and NT, and used the same dose volume ob-
jectives and constraints in all three techniques based on
our experience and a pilot study. Of course, it is possible
that there may be slight differences in the results caused
by the different optimization algorithms used in each of
the unique planning systems.
VMAT-S and HT provided very similar and highly con-
formal plans. HT provided a more homogeneous dose dis-
tribution in the PTV105 (16.7% vs. 40.5%; P = 0.00), but
no significant difference in terms of the HI (1.06 vs. 1.07;
P = 0.25). The integral dose delivered to normal tissue was
also equivalent using VMAT-S and HT in our study. De-
livery of a statistically significant higher integral dose to
normal tissue for has been reported for HT relative to
VMAT in previous studies [20,21]. However, the differ-
ence was small (approximately 3%). The clinical relevance
is very difficult to assess. A study published by D’Souza
and Rosen [22] suggested that the total energy deposited
in a patient is relatively independent of treatment planning
parameters (such as beam orientation or relative weighting
when many beams are used) for deep-seated targets. In
addition, because bladder, rectum and bowel, and pelvis
bone overlapped with the PTV, their maximum doses
were correlated to the minimum dose delivered to the
PTV. In the current study, the V50 for bladder, rectum,
bowel and pelvis bone were all equivalent among three
techniques.
The major benefits of VMAT-S were manifested in the
faster treatment delivery time and lower MU as com-
pared with IMRT and HT. The delivery time for IMRT
is significantly higher than that for VMAT due to the
multiple field arrangement, time to reposition the gantry
and mode up signal of the Clinac for every field. Theaverage treatment delivery time was reduced by more
than 6 minutes using the VMAT plans as compared with
IMRT and HT plans. This reduction in treatment delivery
time is clinically relevant in relation to patient comfort
and infra-fraction motion. Faster delivery could improve
patient adherence to treatment and reduce intra-fractional
motion. In addition, the higher delivery efficiency also
allowed for more time to carry out image-guided radio-
therapy, further reducing the treatment margin and
toxicity. More patients could be treated per day using
VMAT due to the short delivery time. In addition, the
delivery efficiency of the SmartArc plans is higher in
terms of requiring less MUs.
Conclusions
In postoperative WPRT for endometrial cancer, VMAT-
S provided more homogeneous PTV coverage and su-
perior sparing of OARs in high radiation dose regions
than IMRT, without significantly increasing the integral
dose delivered to OARs; however, a greater volume of
normal tissue was found to receive doses of <20 Gy.
VMAT-S significantly improved treatment efficiency in
terms of delivery time and MU relative to IMRT. As
compared with HT, VMAT was able to provide an ap-
proximate 25% reduction in MU and a 7 minute reduc-
tion in treatment time while maintaining comparable
plan quality. The clinical significance of these differ-
ences with regard to dosimetry and radiation delivery
efficiency needs to be further investigated.
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